# Olanzapine Plus Metoclopramide for the Prevention of Opioid-Induced Nausea and Vomiting

> **NCT07208305** · PHASE3 · RECRUITING · sponsor: **Affiliated Hospital of Qinghai University** · enrollment: 222 (estimated)

## Conditions studied

- Nausea
- Vomiting

## Interventions

- **DRUG:** Olanzapine
- **DRUG:** Metoclopramide

## Key facts

- **NCT ID:** NCT07208305
- **Lead sponsor:** Affiliated Hospital of Qinghai University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-03
- **Primary completion:** 2027-12-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 222 (ESTIMATED)
- **Last updated:** 2026-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07208305

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07208305, "Olanzapine Plus Metoclopramide for the Prevention of Opioid-Induced Nausea and Vomiting". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07208305. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*